In a filing, Rhythm Pharmaceuticals Inc revealed its Chief Technical Officer Shulman Joseph unloaded Company’s shares for reported $1.77 million on Sep 02 ’25. In the deal valued at $105.30 per share,16,781 shares were sold. As a result of this transaction, Shulman Joseph now holds 8,509 shares worth roughly $0.9 million.
Then, JOSEPH SHULMAN bought 16,781 shares, generating $1,730,960 in total proceeds.
Before that, Shulman Joseph sold 4,188 shares. Rhythm Pharmaceuticals Inc shares valued at $419,091 were divested by the Chief Technical Officer at a price of $100.07 per share. As a result of the transaction, Shulman Joseph now holds 8,509 shares, worth roughly $0.9 million.
Goldman initiated its Rhythm Pharmaceuticals Inc [RYTM] rating to a Buy in a research note published on July 10, 2025; the price target was $97. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. BofA Securities also remained covering RYTM and has increased its forecast on April 07, 2025 with a “Buy” recommendation from previously “Neutral” rating.
Price Performance Review of RYTM
On Tuesday, Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] saw its stock jump 4.40% to $105.2. Over the last five days, the stock has gained 5.38%. Rhythm Pharmaceuticals Inc shares have risen nearly 119.30% since the year began. Nevertheless, the stocks have risen 87.92% over the past one year.
How much short interest is there in Rhythm Pharmaceuticals Inc?
A steep rise in short interest was recorded in Rhythm Pharmaceuticals Inc stocks on 2025-09-30, growing by 0.61 million shares to a total of 5.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 4.97 million shares. There was a rise of 10.91%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 02, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $80 price target.
